mRNA vaccines protect from the lung microvasculature injury and the capillary blood volume loss occurring in SARS-CoV-2 paucisymptomatic infections
Keywords:
Long COVID; mRNA vaccines; lung function; DLNO and DLco single-breath simultaneous measure; lung microvascular injury; lung capillary blood volumeAbstract
Introduction: The reduction of lung capillary blood volume (Vc) had been identified as the microvascular injury mostly underlying the respiratory Long-COVID syndrome following post-COVID-19 pneumonia. The same kind of injury have been recently also found in several individuals after milder paucisymptomatic SARS-CoV-2 infections. Though current guidelines strongly recommend vaccination, studies aimed to investigate the in vivo protection of anti-SARS-CoV-2 vaccines on lung microvascular targets still are missing to our best knowledge. Aim: to assess the protection of mRNA vaccines from the reduction of lung capillary blood volume (Vc) caused by pauci-symptomatic SARS.CoV-2 infections in vaccinated compared to unvaccinated individuals.
Methods: Non-smoking individuals with recent paucisymptomatic SARS-CoV-2 infection were divided into vaccinated and unvaccinated groups. Lung function parameters, including single-breath diffusing capacity and microvascular blood volume, were compared between groups.
Results: fifty vaccinated and twenty-five unvaccinated well-matched individuals were studied. Differently than usual lung function parameters, only the single-breath simultaneous assessment of sDLCO, sDLNO/sDLCO ratio and Vc allowed to identify the occurrence of the lung microvascular injury with high sensitivity and specificity (p<0.001).
Conclusion: mRNA vaccines proved to exert a high protection from the loss of lung capillary blood volume (Vc) induced by SARS.CoV-2 paucisymptomatic infections (p<0.001). The availability of this non-invasive investigational model should be regarded as a very helpful tool for assessing and comparing in vivo the protective effect of mRNA vaccines on the human microvascular structures of the deep lung.
References
Ashhurst AS, Johansen MD, Maxwell JWC, Stockdale S, Ashley CL, Aggarwa A, et al. Mucosal TLR2-activating protein-based vaccination induces potent pulmonary immunity and protection against SARS-CoV-2 in mice. Nature Commun 2022;13:6972.
Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. China Novel Coronavirus Investigating and Research Team. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 2020;382: 27-33.
Matricardi PM, Dal Negro RW, Nisini R. The first, comprehensive immunological model of COVID-19: implications for prevention, diagnosis, and public health measures. Pediatr Allergy Immunol 2020:31(5):454-70. doi:10.1111/pai.13271.
Guan W, Ni Z, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382:1708-20. https://doi.org/10.1056/NEJMo a2002032
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395:497-506.
Akbarialiabad H, Taghrir MH, Abdollahi A, Ghahramani N, Kumar M, Paydar S, et al. Long COVID, a comprehensive systematic scoping review. Infection 2021;49:1163-86.
Fernandez-de-las-Penas C. Long-COVID: current definition. Infection 2022;50:285-6.
Joshee S, Vatti N, Chang C. Long-Term effects of COVID-19. Mayo Clin. Proc. 2022;97: 579-99.
Yong SJ. Long COVID or post-COVID-19 syndrome: putative pathophysiology, risk factors, and treatments. Infect Dis 2021;53(10):737-54.
Castanares-Zapatero P, Chalon L, Kohn M, Dauvrin M, Detollenaere J, Maertens de Noordhout C, et al. Pathophysiology and mechanism of long COVID: a comprehensive review. Ann Med, 2022;54:1473-87.
Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 2020;323:1061-69.
Iba T, Connors JM, Levy JH. The coagulopathy, endotheliopathy, and vasculitis of COVID-19. Inflamm Res 2020;69: 1181-9.
Mo X, Jian W, Su Z, Chen M, Peng H, Peng P, et al. Abnormal pulmonary function in COVID-19 patients at time of hospital discharge. Eur Respir J 2020;55,2001217. https://doi.org/10.1183/13993 003.01217 -2020;
National Institute for Health and Care Excellence, Scottish Intercollegiate Guidelines Network, Royal College of General practitioners. COVID-19 rapid guideline managing the long-term effects of COVID-19. Dec. 18, 2020. https//www.nice.org.uk/guidance/ng188 (accessed April 30, 2022).
Dal Negro RW, Turco P, Povero M. Long-lasting dyspnea in patients otherwise clinically and radiologically recovered from COVID pneumonia: a probe for checking persisting disorders in capillary lung volume as a cause. Multidiscip Respir Med 2022;17(1):875. doi: 10.4081/mrm.2022
Haque AH, Pant AB. Long COVID: untangling the complex syndrome and the search for therapeutics. Viruses 2023;15:42. https://doi.org/10.3390/v15010042
Halpin SJ, McIvor C, Whyatt G, Adams A, Harvey O, McLean L, et al. Post-discharge symptoms and rehabilitation needs in survivors of COVID-19 infection: a cross-sectional evaluation. J Med Virol 2021;93(2):1013-1022. doi: 10.1002/jmv.26368.
Sykes DL, Holdsworth L, Jawad N, Gunasekera P, Morice AH, Crooks MG. Post-COVID-19 symptom burden: what is Long-COVID and how should we manage it? Lung 2021;199:113-9.
Dal Negro RW, Turco P, Povero M. Phenotyping lung function disorders in respiratory Long-COVID. Brit J Multidisc Adv Studies 2023;4:71-83.
Dal Negro RW, Turco P, Povero M. Persistent Reduction of Lung Capillary Blood Volume as the Major “Deep Lung” Disorder Underlying Respiratory Long-COVID Syndrome. Am J Med and Public Health 2024;5(1):1-8.
Food and Drug Administration. Learn more about COVID-19 vaccines from the FDA. Silver Spring, MD: US Department of Health and Human Services, Food and Drug Administration; 2021. Accessed August 23, 2021. https://www.fda.gov/consumers/consumer-updates/learn-more-about-covid-19-vaccines-fda
CDC. COVID-19: different COVID-19 vaccines. Atlanta, GA: US Department of Health and Human Services, CDC; 2021. Accessed August 25, 2021. https://www.cdc.gov/coronavirus/2019-ncov/vaccines/ different-vaccines.html
Krammer F. SARS-CoV-2 vaccines in development. Nature 2020;586:516-27.
Lavelle EC, Ward RW. -Mucosal vaccines — fortifying the frontiers. Nat Rev Immunol 2022;22:236-50.
Haas EJ, Angulo FJ, McLaughlin JM, Anis E, Singer SR, Khan F, Brooks, et al. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: An observational study using national surveillance data. Lancet 2021;397:1819-29.
Dagan N, Barda N, Kepten E, Miron O, Perchik S, Katz MA, et al. BNT162b2 mRNA COVID-19 Vaccine in a Nationwide Mass Vaccination Setting. N Engl J Med 2021;384:1412-23.
Chung H, He S, Nasreen S, Sundaram ME, Buchan SA, Wilson, SE, et al. Canadian Immunization Research Network (CIRN) Provincial Collaborative Network (PCN) Investigators. Effectiveness of BNT162b2 and mRNA-1273 COVID-19 vaccines against symptomatic SARS-CoV-2 infection and severe COVID-19 outcomes in Ontario, Canada: Test negative design study. BMJ 2021;374:n1943.
Lauring AS, Tenforde MW, Chappell JD, Gaglani M, Ginde AA, Tresa McNeal T, et al. Clinical severity of, and effectiveness of mRNA vaccines against Covid-19 from omicron, delta, and alpha SARS-CoV-2 variants in the United States: prospective observational study. BMJ 2022;376:e069761. http://dx.doi.org/10.1136/bmj‑2021‑069761)
Angel Y, Spitzer A, Henig O, Saiag E, Sprecher E, Padova H, et al. Association Between Vaccination With BNT162b2 and Incidence of Symptomatic and Asymptomatic SARS-CoV-2 Infections Among Health Care Workers. JAMA 2021;325:2457-65.
Pilishvili T, Gierke R, Fleming-Dutra KE, Farrar JL, Mohr NM, Talan DA, et al. Vaccine Effectiveness among Healthcare Personnel Study Team Effectiveness of mRNA COVID-19 Vaccine among, U.S. Health Care Personnel. N Engl J Med 2021;385:e90.
Mahler DA, Wells CK. Evaluation of clinical methods for rating dyspnoea. Chest 1988;93:580-6.
Roughton FJ, Forster RE. Relative importance of diffusion and chemical reaction in determining rate of exchange of gases in the human lung. J Appl Physiol 1957;11:290-302.
Graham BL, Brusasco V, Burgos F, Cooper BG, Jensen R, Kendrick A, et al. ERS/ATS standards for single-breath carbon monoxide uptake in the lung. Eur Respir J 2017;49(1):1600016. doi: 10.1183/13993003.00016-2016
van Kessel SAM, Olde Hartman TC, Lucassen PLBJ, van Jaarsveld CHM. Postacute and long-COVID-19 symptoms in patients with mild diseases: a systematic review. Fam Pract 2022;39:159-67.
Huang C, Huang L, Wang Y, Li X, Ren L, Gu X, et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet 2021;397:220-32.
Tian S, Xiong Y, Liu H, Niu L, Guo J, Liao M, et al. Pathological study of the 2019 novel coronavirus disease (COVID-19) through postmortem core biopsies. Mod Pathol 2020; 33(6):1007-1014. https://doi.org/10.1038/s4137 9-020-0536
Dhawan RT, Gopalan D, Howard L, Vicente A, Park M, Manalan K, et al. Beyond the clot: perfusion imaging of the pulmonary vasculature after COVID-19. Lancet Respir Med 2021;9:107-16.
Wickman D, Sperhake JP, Lutgehetmann M, Steurer S, Edler C, Heinemann A, et al. Autopsy findings and venous thromboembolism in patients with COVID-19: a prospective cohort study. Ann Intern Med 2020;173:268-77.
Libby P, Luscher T. COVID-19 is in the end, an endothelial disease. Eur Heart J 2020;41:3038-44.
Iba T, Connors JM, Levy JH. The coagulopathy, endotheliopathy, and vasculitis of COVID-19. Inflamm Res 2020;69:1181-9.
Frija-Masson J, Debray MP, Gilbert M, Lescure FX, Travert F, Borie R, et al. Functional characteristics of patients with SARS-CoV- 2 pneumonia at 30 days post-infection. Eur Respir J 2020;56:2001754. https://doi.org/10.1183/13993 003.01754.
Mo X, Jian W, Su Z, Chen M, Peng H, Peng P, et al. Abnormal pulmonary function in COVID-19 patients at time of hospital discharge. Eur Respir J 2020;55:2001217. https://doi.org/10.1183/13993 003.01217 -2020)
Gibson QH, Roughton FJW. The kinetics and equilibria of the reactions of nitric oxide with sheep haemoglobin. J Phys 1957;136:507-24.
Zavorsky GS, van der Lee I. Can the measurement of pulmonary diffusing capacity for nitric oxide replace the measurement of pulmonary diffusing capacity for carbon monoxide? Respir Physiol Neurobiol 2017;241:9-16.
Zavorsky GS, Hsia CCW, Hughes MB, Borland CD, Guénard H, van der Lee I, et al. Standardization and application of the single-breath determination of nitric oxide uptake in the lung. Eur Respir J 2017;49:1600962. doi: 10.1183/13993003.00962-2016
Borland CDR, Hughes JMB. Lung diffusing capacities (DL) for nitric oxide (NO) and carbon monoxide (CO): The evolving story. Compr Physiol 2020;10:73-97.
George PM, Barratt SL, Condliffe R, Desai SR, Devaraj A, Forrest I, et al. Respiratory follow-up of patients with COVID-19 pneumonia. Thorax 2020;75:1009-16.
Osiaevi I, Schulze A, Evers G, Harmening K, Vink H, Kumpers P, et al. Persistent capillary rarefication in long COVID syndrome. Angiogenesis 2023 Feb;26(1):53-61. doi: 10.1007/s10456-022-09850-9.
Self WH, Tenforde MW, Rhoads JP, Gaglani M, Adit A, Ginde AA et al. Comparative Effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) Vaccines in Preventing COVID-19 Hospitalizations Among Adults Without Immunocompromising Conditions — United States, March–August 2021. MMWR 2021;70(38):1337-43.
Graham BS. Advances in antiviral vaccine development. Immunol Rev 2013;255(1):230-42. https://doi.org/10.1111/imr.1209890
Notarte KI, Catahay JA, Velasco JV, Pastrana A, Ver AT, Pangilinan FC, et al. Impact of Covid-19 vaccination on the risk of developing long-COVID and on existing long-COVID symptoms. A systematic review. EClinicalMedicine 2022;53:101624.
Haque AH, Pant AB. Long COVID: untangling the complex syndrome and the search for therapeutics. Viruses 2023;15:42. https://doi.org/10.3390/v15010042
Colombo D, Del Nonno F, Marchioni L, Lalle E, Gallì P, Vaia F, et al. Autopsies Revealed Pathological Features of COVID-19 in Unvaccinated vs. Vaccinated Patients. Biomedicines 2023;11:551. https://doi.org/10.3390/biomedicines11020551)
Published
Issue
Section
License
Copyright (c) 2024 The Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Mattioli 1885 has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
How to Cite
